Skip to main content
SpringerLink
Log in

Physical Activity and Genitourinary Cancer Survivorship

  • Chapter
  • First Online:
Physical Activity and Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 186))

Abstract

In this chapter we discuss common toxicities arising from genitourinary cancer treatments, in particular the adverse effects from androgen deprivation therapy (ADT) for prostate cancer given its well established detrimental effects on physical, physiological, and psychological function, and existing physical activity research in the postdiagnosis period including studies focusing on supportive care and some limited data on disease outcomes. Overall, consistent positive outcomes have been reported across studies showing that exercise is beneficial to reduce a number of treatment-related toxicities and improve symptoms. Additional studies are needed in genitourinary cancers other than prostate to establish specific physical activity requirements and implementation strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 209.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 269.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 269.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Basaria S, Lieb J 2nd, Tang AM et al (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56(6):779–786

    Article  CAS  Google Scholar 

  • Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106(3): 581–588

    Article  PubMed  CAS  Google Scholar 

  • Blanchard MC, Stein KD, Baker F et al (2004) Association between current lifestyle behaviors and health-related quality of life in breast, colorectal, and prostate cancer survivors. Psychol Health 19(1):1–13

    Article  Google Scholar 

  • Bong GW, Clarke HS Jr, Hancock WC, Keane TE (2008) Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 71(6):1177–1180

    Article  PubMed  Google Scholar 

  • Braga-Basaria M, Dobs AS, Muller DC et al (2006a) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24(24):3979–3983

    Article  PubMed  Google Scholar 

  • Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S (2006b) Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18: 494–498

    Article  PubMed  CAS  Google Scholar 

  • Carmack Taylor CL, Demoor C, Smith MA et al (2006) Active for life after cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 15(10):847–862

    Article  PubMed  Google Scholar 

  • Catalona WJ, Ramos CG, Carvalhal GF (1999) Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 49(5):282–296

    Article  PubMed  CAS  Google Scholar 

  • Chen Z, Maricic M, Nguyen P et al (2002) Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95(10):2136–2144

    Article  PubMed  Google Scholar 

  • Chodak GW (1998) Comparing treatments for localized prostate cancer–persisting uncertainty. JAMA 280(11):1008–1010

    Article  PubMed  CAS  Google Scholar 

  • Courneya KS (2003) Exercise in cancer survivors: an overview of research. Med Sci Sports Exerc 35(11):1846–1852

    Article  PubMed  Google Scholar 

  • Culos-Reed SN, Robinson JL, Lau H, O’Connor K, Keats MR (2007) Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol 29(1):118–127

    PubMed  Google Scholar 

  • Culos-Reed SN, Robinson JW, Lau H et al (2009) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 18(5):591–599

    Article  PubMed  Google Scholar 

  • D’Amico AV, Denham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25(17):2420–2425

    Article  PubMed  Google Scholar 

  • Dahn JR, Penedo FJ, Molton I et al (2005) Physical activity and sexual functioning after radiotherapy for prostate cancer: beneficial effects for patients undergoing external beam radiotherapy. Urology 65(5):953–958

    Article  PubMed  Google Scholar 

  • Demark-Wahnefried W, Clipp EC, Lipkus IM et al (2007) Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol 25(19): 2709–2718

    Article  PubMed  Google Scholar 

  • Demark-Wahnefried W, Clipp EC, Morey MC et al (2004) Physical function and associations with diet and exercise: Results of a cross-sectional survey among elders with breast or prostate cancer. Int J Behav Nutr Phys Act 1(1):16

    Article  PubMed  Google Scholar 

  • Demark-Wahnefried W, Clipp EC, Morey MC et al (2006) Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. J Clin Oncol 24(21):3465–3473

    Article  PubMed  Google Scholar 

  • Doyle C, Kushi LH, Byers T et al (2006) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 56(6): 323–353

    Article  PubMed  Google Scholar 

  • Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ (2002) The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95(2):287–295

    Article  PubMed  Google Scholar 

  • Galvão DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. J Clin Oncol 23(4):899–909

    Article  PubMed  Google Scholar 

  • Galvão DA, Newton RU, Taaffe DR, Spry N (2008a) Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol 5(6):306–307

    PubMed  Google Scholar 

  • Galvão DA, Nosaka K, Taaffe DR et al (2008b) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 11(2):160–165

    Article  PubMed  Google Scholar 

  • Galvão DA, Nosaka K, Taaffe DR et al (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38(12):2045–2052

    Article  PubMed  Google Scholar 

  • Galvão DA, Spry N, Taaffe DR et al (2009a) A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer 9(1):419

    Article  PubMed  Google Scholar 

  • Galvão DA, Spry NA, Taaffe DR et al (2008c) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102(1):44–47

    Article  PubMed  Google Scholar 

  • Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2): 340–347

    Article  PubMed  Google Scholar 

  • Galvão DA, Taaffe DR, Spry N et al (2009b) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12(2):198–203

    Article  PubMed  Google Scholar 

  • Galvão DA, Taaffe DR, Spry N, Newton RU (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 10(4):340–346

    Article  PubMed  Google Scholar 

  • Greenspan SL, Coates P, Sereika SM et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–6417

    Article  PubMed  CAS  Google Scholar 

  • Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859–864

    Article  PubMed  Google Scholar 

  • Hakkinen K, Pakarinen A, Kraemer WJ, Newton RU, Alen M (2000) Basal concentrations and acute responses of serum hormones and strength development during heavy resistance training in middle-aged and elderly men and women. J Gerontol A Biol Sci Med Sci 55(2):B95–B105

    Article  PubMed  CAS  Google Scholar 

  • Hara I, Miyake H, Hara S et al (2002) Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement. BJU Int 89(1): 10–13

    Article  PubMed  CAS  Google Scholar 

  • Herr HW (1997) Quality of life in prostate cancer patients. CA Cancer J Clin 47(4):207–217

    Article  PubMed  CAS  Google Scholar 

  • Hickok JT, Roscoe JA, Morrow GR et al (2005) Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer 104(8): 1772–1778

    Article  PubMed  Google Scholar 

  • Higano CS (2003) Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 21(5):392–398

    Article  PubMed  CAS  Google Scholar 

  • Hussain MH, Wood DP, Bajorin DF et al (2009) Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 27(34): 5680–5684

    Article  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96

    Article  PubMed  Google Scholar 

  • Kaisary AV (2005) Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis 8(2):140–151

    Article  PubMed  CAS  Google Scholar 

  • Kaku H, Saika T, Tsushima T et al (2006) Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66(4):439–444

    Article  PubMed  CAS  Google Scholar 

  • Karvinen KH, Courneya KS, North S, Venner P (2007a) Associations between exercise and quality of life in bladder cancer survivors: a population-based study. Cancer Epidemiol Biomark Prev 16(5):984–990

    Article  Google Scholar 

  • Karvinen KH, Courneya KS, Plotnikoff RC et al (2009) A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. Support Care Cancer 17(2):171–179

    Article  PubMed  Google Scholar 

  • Karvinen KH, Courneya KS, Venner P, North S (2007b) Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. J Cancer Surviv 1(1): 27–34

    Article  PubMed  Google Scholar 

  • Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2009) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46

    Article  PubMed  Google Scholar 

  • Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456

    Article  PubMed  CAS  Google Scholar 

  • Kraemer WJ, Hakkinen K, Newton RU et al (1999) Effects of heavy-resistance training on hormonal response patterns in younger vs. older men. J Appl Physiol 87(3):982–992

    PubMed  CAS  Google Scholar 

  • Lee H, McGovern K, Finkelstein JS, Smith MR (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104(8): 1633–1637

    Article  PubMed  CAS  Google Scholar 

  • Lu-Yao GL, Yao SL (1997) Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349(9056): 906–910

    Article  PubMed  CAS  Google Scholar 

  • McCredie M, Cox B (1998) Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 169(1):9–10

    PubMed  CAS  Google Scholar 

  • Michaelson MD, Cotter SE, Gargollo PC et al (2008) Management of complications of prostate cancer treatment. CA Cancer J Clin 58(4): 196–213

    Article  PubMed  Google Scholar 

  • Miller DC, Sanda MG, Dunn RL et al (2005) Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23(12): 2772–2780

    Article  PubMed  Google Scholar 

  • Monga U, Garber SL, Thornby J et al (2007) Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 88(11): 1416–1422

    Article  PubMed  Google Scholar 

  • Morey MC, Snyder DC, Sloane R et al (2009) Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. Jama 301(18):1883–1891

    Article  PubMed  CAS  Google Scholar 

  • Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163(6): 1632–1642

    Article  PubMed  CAS  Google Scholar 

  • Newton RU, Taaffe DR, Spry N et al (2009) A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer 9:210

    Article  PubMed  Google Scholar 

  • Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refrac-tory prostate cancer. J Clin Oncol 23(15): 3343–3351

    Article  PubMed  CAS  Google Scholar 

  • Petrella JK, Kim JS, Tuggle SC, Hall SR, Bamman MM (2005) Age differences in knee extension power, contractile velocity, and fatigability. J Appl Physiol 98(1):211–220

    Article  PubMed  Google Scholar 

  • Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513–1520

    Article  PubMed  CAS  Google Scholar 

  • Ransohoff DF, McNaughton Collins M, Fowler FJ (2002) Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113(8):663–667

    Article  PubMed  Google Scholar 

  • Rashid MH, Chaudhary UB (2004) Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9(3):295–301

    Article  PubMed  CAS  Google Scholar 

  • Saigal CS, Gore JL, Krupski TL et al (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110(7):1493–500

    Article  PubMed  CAS  Google Scholar 

  • Schmitz KH, Holtzman J, Courneya KS et al (2005) Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 14(7): 1588–1595

    Article  Google Scholar 

  • Segal RJ, Reid RD, Courneya KS et al (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21(9):1653–1659

    Article  PubMed  Google Scholar 

  • Segal RJ, Reid RD, Courneya KS et al (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27(3): 344–351

    Article  PubMed  Google Scholar 

  • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005a) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2): 154–164

    Article  PubMed  CAS  Google Scholar 

  • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166(4): 465–471

    PubMed  Google Scholar 

  • Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005b) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8):1615–1624

    Article  PubMed  CAS  Google Scholar 

  • Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. Jama 294(2):238–244

    Article  PubMed  CAS  Google Scholar 

  • Smith JC, Bennett S, Evans LM et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86(9):4261–4267

    Article  PubMed  CAS  Google Scholar 

  • Smith MR (2004) Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63(4):742–745

    Article  PubMed  Google Scholar 

  • Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87(2):599–603

    Article  PubMed  CAS  Google Scholar 

  • Smith MR, Lee H, McGovern F et al (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112(10):2188–2194

    Article  PubMed  CAS  Google Scholar 

  • Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91(4): 1305–1308

    Article  PubMed  CAS  Google Scholar 

  • Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23(31):7897–7903

    Article  PubMed  CAS  Google Scholar 

  • Spry NA, Galvão DA, Davies R et al (2009) Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int 104(6):806–812

    Article  PubMed  CAS  Google Scholar 

  • Spry NA, Kristjanson L, Hooton B et al (2006) Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42(8):1083–1092

    Article  PubMed  CAS  Google Scholar 

  • Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. Jama 283(3):354–360

    Article  PubMed  CAS  Google Scholar 

  • Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350(22):2239–2246

    Article  PubMed  CAS  Google Scholar 

  • Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99(20): 1516–1524

    Article  PubMed  Google Scholar 

  • Van Kampen M, De Weerdt W, Van Poppel H et al (2000) Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. Lancet 355(9198):98–102

    Article  PubMed  Google Scholar 

  • van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL (2008) Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol 68(2):172–177

    Article  PubMed  Google Scholar 

  • Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352(9141):1691–1696

    Article  PubMed  CAS  Google Scholar 

  • von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077

    PubMed  Google Scholar 

  • Windsor PM, Nicol KF, Potter J (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101(3):550–557

    Article  PubMed  Google Scholar 

  • Winer E, Gralow J, Diller L et al (2009) Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol 27(5):812–826

    Article  PubMed  Google Scholar 

  • Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS (2010) Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol 183(2):629–633

    Article  PubMed  Google Scholar 

  • Yan Y, Carvalhal GF, Catalona WJ, Young JD (2000) Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88(5):1122–1130

    Article  PubMed  CAS  Google Scholar 

  • Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to exp-and the knowledge base. J Clin Oncol 19(4): 1147–1151

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edith Cowan University Health and Wellness Institute, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia

    Daniel A. Galvão & Robert U. Newton

  2. School of Human Movement Studies, University of Queensland, Brisbane, QLD, Australia

    Dennis R. Taaffe

  3. Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia

    Nigel Spry

Authors
  1. Daniel A. Galvão
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dennis R. Taaffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nigel Spry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert U. Newton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel A. Galvão .

Editor information

Editors and Affiliations

  1. Fac. Physical Education & Recreation, University of Alberta, Van Vliet Center E488, Edmonton, T6G 2H9, Alberta, Canada

    Kerry S. Courneya

  2. Div. Population Health & Information, Tom Baker Cancer Centre, 29th Street NW., 1331, Calgary, T2N 4N2, Alberta, Canada

    Christine M. Friedenreich

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Galvão, D.A., Taaffe, D.R., Spry, N., Newton, R.U. (2010). Physical Activity and Genitourinary Cancer Survivorship. In: Courneya, K., Friedenreich, C. (eds) Physical Activity and Cancer. Recent Results in Cancer Research, vol 186. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04231-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04231-7_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04230-0

  • Online ISBN: 978-3-642-04231-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation